Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA II Reviews Start Strong With High First-Cycle Approval Rate

Executive Summary

Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration. 

You may also be interested in...



Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018

US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.

Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018

US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.

US FDA's Generics Program Reaches 'Steady State' Milestone

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel